STC2: A Potential Drug Target for Insulin Secretion and Cancer

Target Name: STC2

NCBI ID: G8614

STC2

STC2: A Potential Drug Target for Insulin Secretion and Cancer

STC2 (Stann insulin 2) is a protein that is expressed in pancreatic beta cells, which produce insulin to regulate blood sugar levels. The molecule has been identified as a potential drug target for several diseases, including type 2 diabetes.

One of the reasons why STC2 has potential as a drug target is because it is involved in the regulation of insulin secretion. Insulin is produced by the pancreatic beta cells and is responsible for regulating the levels of glucose in the blood. STC2 has been shown to play a role in the regulation of insulin secretion by controlling the movement of insulin granules into the cell.

Another potential drug target for STC2 is its role in pancreatic cancer development. Studies have shown that STC2 is highly expressed in pancreatic cancer cells and that inhibiting its activity may have a positive effect on cancer treatment.

In addition to its potential as a drug target, STC2 has also been shown to be a potential biomarker for pancreatic cancer. The presence of STC2 in pancreatic cancer cells has been used as a diagnostic marker for this disease.

Despite the potential benefits of targeting STC2, there are also concerns about the potential side effects of such a treatment. Studies are needed to fully understand the risks and benefits of using STC2 as a drug target, particularly in humans.

In conclusion, STC2 is a protein that has been identified as a potential drug target for several diseases, including type 2 diabetes and pancreatic cancer. Further research is needed to fully understand its potential as a drug and to determine the safety and effectiveness of targeting it .

Protein Name: Stanniocalcin 2

Functions: Has an anti-hypocalcemic action on calcium and phosphate homeostasis

The "STC2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about STC2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets